A total of 237 EGFR-mutation-positive, advanced NSCLC patients, who received first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR-TKIs as first-line palliative chemotherapy, were analyzed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.